Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10626167
APP PUB NO 20180009879A1
SERIAL NO

15546422

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is in the field of monoclonal antibodies suitable for passive immunotherapy of Herpes Simplex Virus infections and relates to human monoclonal antibodies or fragments of said antibodies, which bind and neutralize HSV-1 and HSV-2, and their use in the prophylaxis or treatment of HSV-1 or HSV-2-associated diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
POLICHEM S ALUXEMBURG LUXEMBURG CITY LUXEMBOURG LUXEMBOURG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Burioni, Roberto Segrate, IT 24 115
Clementi, Massimo Milan, IT 19 92
Concas, Daniela Zurich, CH 3 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 21, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 21, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00